scholarly journals Feasibility of Using Masticatory Muscles to Assess Skeletal Muscle Mass in Patients with Oral Cavity Cancer

2019 ◽  
Author(s):  
Sheng-Wei Chang ◽  
Cheng-Ming Hsu ◽  
Yuan-Hsiung Tsai ◽  
Geng-He Chang ◽  
Ming-Shao Tsai ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Oral Cavity ◽  
Head And Neck ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Masticatory Muscles ◽  
Ct Scans ◽  
Abdominal Ct ◽  
Oral Cancer Patients ◽  
Mandibular Notch

Abstract Background Sarcopenia is typically assessed using abdominal computed tomography (CT) scans, which are not obtained routinely in patients with oral cavity cancer. In order to investigate the feasibility of using masticatory muscles to assess general skeletal muscle mass (SMM) in oral cancer patients, we aimed to correlate the masticatory SMM evaluated on head and neck CT-images with the SMM measurement at the level of L3 on abdominal CT-scans. Methods The abdominal and head and neck CT-scans of the oral cavity squamous cell carcinoma (OSCC, n = 54) and trauma (n = 50) patients were analyzed retrospectively. All muscles at the L3 level were delineated on abdominal CT scans, and skeletal muscles at the mandibular notch level and C3 level were delineated on head and neck CT scans. Cross-sectional area (CSA) of the muscles at the mandibular notch and C3 level were compared to skeletal muscle CSA at the L3 level using linear regression, and a multivariate linear regression model was also calculated. Results The OSCC patients had significantly smaller muscle CSA at the mandibular notch level than trauma patients (1221.4 vs. 1512.2 mm2, p = 0.006). Masticatory muscle CSA strongly predicted the L3 muscle CSA (r = 0.880, p < 0.001), and this correlation was stronger in the multivariate model including age, body weight, and sex (r = 0.898, p < 0.001). Conclusions Evaluation of the masticatory skeletal muscle mass on head and neck CT images is simple, feasible, and may be an alternative to abdominal CT scans. Assessment of masticatory muscle at mandibular notch can be performed using routinely obtained scans without additional imaging or cost. Identifying patients at risk of being sarcopenic may select oral cancer patients for nutritional intervention and appropriate treatment modality to improve their prognosis.

scholarly journals Skeletal muscle mass and sarcopenia can be determined with 1.5-T and 3-T neck MRI scans, in the event that no neck CT scan is performed

2020 ◽  
Author(s):  
Aniek T. Zwart ◽  
Jan-Niklas Becker ◽  
Maria J. Lamers ◽  
Rudi A. J. O. Dierckx ◽  
Geertruida H. de Bock ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Correlation Coefficients ◽  
Adverse Outcomes ◽  
Ct Scans ◽  
Mri Scans ◽  
Ct And Mri

Abstract Objectives Cross-sectional area (CSA) measurements of the neck musculature at the level of third cervical vertebra (C3) on CT scans are used to diagnose radiological sarcopenia, which is related to multiple adverse outcomes in head and neck cancer (HNC) patients. Alternatively, these assessments are performed with neck MRI, which has not been validated so far. For that, the objective was to evaluate whether skeletal muscle mass and sarcopenia can be assessed on neck MRI scans. Methods HNC patients were included between November 2014 and November 2018 from a prospective data-biobank. CSAs of the neck musculature at the C3 level were measured on CT (n = 125) and MRI neck scans (n = 92 on 1.5-T, n = 33 on 3-T). Measurements were converted into skeletal muscle index (SMI), and sarcopenia was defined (SMI < 43.2 cm2/m2). Pearson correlation coefficients, Bland–Altman plots, McNemar test, Cohen’s kappa coefficients, and interclass correlation coefficients (ICCs) were estimated. Results CT and MRI correlated highly on CSA and SMI (r = 0.958–0.998, p < 0.001). The Bland–Altman plots showed a nihil mean ΔSMI (− 0.13–0.44 cm2/m2). There was no significant difference between CT and MRI in diagnosing sarcopenia (McNemar, p = 0.5–1.0). Agreement on sarcopenia diagnosis was good with κ = 0.956–0.978 and κ = 0.870–0.933, for 1.5-T and 3-T respectively. Observer ICCs in MRI were excellent. In general, T2-weighted images had the best correlation and agreement with CT. Conclusions Skeletal muscle mass and sarcopenia can interchangeably be assessed on CT and 1.5-T and 3-T MRI neck scans. This allows future clinical outcome assessment during treatment irrespective of used modality. Key Points • Screening for low amount of skeletal muscle mass is usually measured on neck CT scans and is highly clinical relevant as it is related to multiple adverse outcomes in head and neck cancer patients. • We found that skeletal muscle mass and sarcopenia determined on CT and 1.5-T and 3-T MRI neck scans at the C3 level can be used interchangeably. • When CT imaging of the neck is missing for skeletal muscle mass analysis, patients can be assessed with 1.5-T or 3-T neck MRIs.

scholarly journals CT‐measured skeletal muscle mass used to assess frailty in patients with head and neck cancer

2019 ◽  
Vol 10 (5) ◽  
pp. 1060-1069 ◽  
Author(s):  
Aniek T. Zwart ◽  
Anouk Hoorn ◽  
Peter M.A. Ooijen ◽  
Roel J.H.M. Steenbakkers ◽  
Geertruida H. Bock ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Muscle Mass ◽  
Neck Cancer ◽  
Skeletal Muscle Mass

scholarly journals The Combination of Low Skeletal Muscle Mass and High Tumor Interleukin-6 Associates with Decreased Survival in Clear Cell Renal Cell Carcinoma

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1605
Author(s):  
Joshua K. Kays ◽  
Leonidas G. Koniaris ◽  
Caleb A. Cooper ◽  
Roberto Pili ◽  
Guanglong Jiang ◽  
...  
Keyword(s):  
Gene Expression ◽  
Skeletal Muscle ◽  
Overall Survival ◽  
Muscle Mass ◽  
Interleukin 6 ◽  
Skeletal Muscle Mass ◽  
Clear Cell ◽  
Cytokine Gene Expression ◽  
Ct Scans ◽  
Adipose Mass

Clear cell renal carcinoma (ccRCC) is frequently associated with cachexia which is itself associated with decreased survival and quality of life. We examined relationships among body phenotype, tumor gene expression, and survival. Demographic, clinical, computed tomography (CT) scans and tumor RNASeq for 217 ccRCC patients were acquired from the Cancer Imaging Archive and The Cancer Genome Atlas (TCGA). Skeletal muscle and fat masses measured from CT scans and tumor cytokine gene expression were compared with survival by univariate and multivariate analysis. Patients in the lowest skeletal muscle mass (SKM) quartile had significantly shorter overall survival versus the top three SKM quartiles. Patients who fell into the lowest quartiles for visceral adipose mass (VAT) and subcutaneous adipose mass (SCAT) also demonstrated significantly shorter overall survival. Multiple tumor cytokines correlated with mortality, most strongly interleukin-6 (IL-6); high IL-6 expression was associated with significantly decreased survival. The combination of low SKM/high IL-6 was associated with significantly lower overall survival compared to high SKM/low IL-6 expression (26.1 months vs. not reached; p < 0.001) and an increased risk of mortality (HR = 5.95; 95% CI = 2.86–12.38). In conclusion, tumor cytokine expression, body composition, and survival are closely related, with low SKM/high IL-6 expression portending worse prognosis in ccRCC.

scholarly journals The association of cisplatin pharmacokinetics and skeletal muscle mass in patients with head and neck cancer: The prospective PLATISMA study

2021 ◽  
Author(s):  
Najiba Chargi ◽  
Laura Molenaar-Kuijsten ◽  
Laura F.J. Huiskamp ◽  
Lot A. Devriese ◽  
Remco de Bree ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Muscle Mass ◽  
Neck Cancer ◽  
Skeletal Muscle Mass

Toxicity of induction chemotherapy in head and neck cancer: The central role of skeletal muscle mass

Head & Neck ◽  
2021 ◽  
Author(s):  
Alexane Lere‐Chevaleyre ◽  
Maureen Bernadach ◽  
Céline Lambert ◽  
Lucie Cassagne ◽  
Mathilde Puechmaille ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Muscle Mass ◽  
Induction Chemotherapy ◽  
Neck Cancer ◽  
Skeletal Muscle Mass

CT-based skeletal muscle mass estimation in head and neck cancer (HNC)

2021 ◽  
Author(s):  
Stephanie Mangesius ◽  
Daniel Dejaco ◽  
Lukas Haider ◽  
Julian Mangesius ◽  
Hanna Kranebitter ◽  
...  
Keyword(s):  
Skeletal Muscle ◽  
Head And Neck Cancer ◽  
Head And Neck ◽  
Muscle Mass ◽  
Neck Cancer ◽  
Skeletal Muscle Mass ◽  
Mass Estimation

The association of skeletal muscle mass and cisplatin pharmacokinetics in head and neck cancer patients: The prospective PLATISMA study.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 6021-6021
Author(s):  
Laura Molenaar-Kuijsten ◽  
Najiba Chargi ◽  
Lot Devriese ◽  
Remco de Bree ◽  
Alwin Huitema
Keyword(s):  
Skeletal Muscle ◽  
Body Size ◽  
Head And Neck ◽  
Muscle Mass ◽  
Skeletal Muscle Mass ◽  
Locally Advanced ◽  
The Body ◽  
Fat Free Mass ◽  
Pharmacokinetic Analysis ◽  
Severe Toxicity

6021 Background: Locally advanced head and neck squamous cell carcinoma (HNSCC) is commonly treated with cisplatin-based chemoradiotherapy (CRT). Cisplatin is associated with severe toxicity, which negatively affects survival. In recent years, a relationship between low skeletal muscle mass (SMM) and toxicity has been described. This increased toxicity may be related to an altered cisplatin distribution and binding in the fat-free body mass, of which SMM is the largest contributor. This study aims to investigate the association between cisplatin pharmacokinetics and SMM in HNSCC patients. Methods: We performed a prospective observational study in HNSCC patients treated with CRT with cisplatin. Patients received standard-of-care chemotherapy with three cycles of cisplatin, at a dose level of 100 mg/m2 per cycle. Quantitative data on body size descriptors including SMM, measured on computed tomography scans, and cisplatin pharmacokinetics (total and ultrafilterable plasma concentration) were collected, as well as data on toxicity. Results: 45 evaluable patients were included in the study. A large proportion of the study population had a low SMM (46.7%). The majority of patients (57.8%) experienced cisplatin dose limiting toxicities. Pharmacokinetic analysis showed a significant relationship between cisplatin pharmacokinetics and the body size descriptors SMM, weight, fat-free mass, and body surface area ( p< 0.005). In a simulation, patients with a low SMM were predicted to reach higher bound cisplatin concentrations. The higher concentration of bound cisplatin could be seen as a reflection of the smaller volume of distribution, and could thereby explain the increased toxicity in patients with a low SMM. Conclusions: We found an association between cisplatin pharmacokinetics and SMM. Patients with a low SMM were predicted to reach higher bound cisplatin concentrations, which could be an explanation for the increased toxicity in this patient group. Clinical trial information: Trial NL7469 (NTR7711).

Sign in / Sign up

Export Citation Format

Share Document